Sepsis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Sepsis Market Outlook

Thelansis’s “Sepsis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sepsis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sepsis Overview

Sepsis is defined as infected patients with a rise of ≥2 Sequential Organ Failure Score (SOFA) points. Microorganisms in sepsis carry specific pathogen-associated molecular patterns, binding to pattern recognition receptors (PRRs), triggering immune cells to produce proinflammatory cytokines. Another PRR stimulation mechanism is the damage-associated pathogen pattern, resulting from molecular particle release due to invasive microbes causing cell damage. PRR binding releases pro-inflammatory and anti-inflammatory mediators, contributing to tissue damage and compromised immune response. Compliance with sepsis bundles can be challenging due to the complexity of identifying and treating sepsis. In the United States, sepsis is the leading cause of inpatient death, impacting 1.7 million adults annually and contributing to 270,000 deaths, accounting for about 20% of global annual deaths. The rising incidence of sepsis is attributed to factors such as antibiotic resistance, an aging population, and increased use of invasive procedures. Predisposing factors to septic shock include cancer, immunodeficiency, chronic organ failure, and genetic factors. Early detection, facilitated by screening tools, is crucial for improved patient outcomes. Routine screening for sepsis, especially in patients admitted for severe infections, is essential for early diagnosis and prompt therapy implementation. Specialized sepsis screening tools for ICU care have been developed to expedite this process, emphasizing the critical importance of reducing the time to diagnosis for all patients.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: